Genincode

Genincode CROIC

The Cash Return on Invested Capital (CROIC) of Genincode (GENI.L) as of Oct 27, 2026 is -1,522.96 %. In the previous year, Cash Return on Invested Capital (CROIC) was -383.69 % — a change of 296.93% (lower).

CROIC

-1,522.96 %

YoY

296.93%

Last updated:

Cash Return on Invested Capital (CROIC) of Genincode is 2025 -1,522.96 % . Cash Return on Invested Capital (CROIC) of Genincode was 2024 -383.69 % . It decreases by 296.93% lower compared to the previous year.

The Genincode CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
287.38 GBP
Jan 1, 2020
-59.51 GBP
Jan 1, 2021
-23.10 GBP
Jan 1, 2022
-55.86 GBP
Jan 1, 2023
-475.06 GBP
Jan 1, 2024
-383.69 GBP
Jan 1, 2025
-1,522.96 GBP
The Genincode CROIC history
YEARCROICYoY
-1,522.96 %+296.93%
-383.69 %-19.23%
-475.06 %+750.39%
-55.86 %+141.82%
-23.10 %-61.18%
-59.51 %-120.71%
287.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genincode Stock analysis

What does Genincode do? GENinCode Plc generates revenue through its genetic risk assessment products for cardiovascular disease, including Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo, and Thrombo Incode Reproductive Health. The company targets healthcare practitioners who use its genomic precision testing, combining polygenic technology, molecular testing, genotyping, sequencing, and AI bioinformatics to assess patient DNA risk. Its products integrate genetic and clinical data to provide predictive care strategies for cardiovascular disease prevention. The firm serves medical professionals seeking advanced tools for patient risk evaluation and treatment planning. The company's wholly owned subsidiaries, GENinCode S.L.U. and GENinCode U.S. INC., support its global operations in risk assessment and prevention services. GENinCode Plc's focus on cardiovascular disease risk assessment leverages AI-driven bioinformatics to deliver tailored preventative care solutions. Healthcare providers utilize its comprehensive testing suite to enhance clinical decision-making and patient outcomes in cardiovascular health management. Genincode is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genincode stock

Cash Return on Invested Capital (CROIC) of Genincode is -1,522.96 % in 2025.

Cash Return on Invested Capital (CROIC) of Genincode changed from -383.69 % to -1,522.96 %, representing a 296.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Genincode since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Genincode with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genincode

All Key Metrics — Genincode